🇺🇸 FDA
Patent

US 8778608

CA9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma

granted A61PA61P35/00A61P35/04

Quick answer

US patent 8778608 (CA9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma) held by The Regents of the University of California expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jul 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P35/00, A61P35/04, A61P37/04